festinavir
BMS licences phase II HIV compound festinavir
December 22, 2010Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor
Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
